Myriad Genetics
American biotechnology company
MYGN Nasdaq
ISIN US62855J1043 SEC CIK 899923 LEI 52990044IHUOUMETT163
Follow Myriad Genetics
Weekly email: filings, results
Revenue, last quarter
$202.7M
−1.5% vs same quarter last year
Net income
−$43.9M
−60.2% vs same quarter last year
EPS, diluted
−$0.46
−58.6% vs same quarter last year
Operating cash flow
−$6.5M
−130.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $824.5M | −$366M |
| FY24 | $837.6M | −$127M |
| FY23 | $753.2M | −$263M |
| FY22 | $678.4M | −$112M |
| FY21 | $690.6M | −$27M |
| FY20 | $638.6M | −$199.5M |
| FY19 | $851.1M | $4.6M |
| FY18 | $743.7M | $133.3M |
| FY17 | $728.7M | $17.4M |
| FY16 | $740.5M | $117.2M |
| FY15 | $722.5M | $79.8M |
| FY14 | $778.2M | $176.2M |
| FY13 | $613.2M | $147.2M |
| FY12 | $496M | $112.2M |
| FY11 | $402.1M | $100.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 69.9% | −47% | −44.4% |
| FY24 | 69.9% | −14.7% | −15.2% |
| FY23 | 68.6% | −34.2% | −34.9% |
| FY22 | 70.2% | −20.7% | −16.5% |
| FY21 | - | −27.6% | −3.9% |
| FY20 | - | −36.3% | −31.2% |
| FY19 | - | 0.9% | 0.5% |
| FY18 | - | 16.4% | 17.9% |
| FY17 | 80.1% | 6% | 2.4% |
| FY16 | 82.1% | 20.7% | 15.8% |
| FY15 | 81.6% | 18.5% | 11% |
| FY14 | 87.7% | 35.3% | 22.6% |
| FY13 | 89.5% | 37.2% | 24% |
| FY12 | 89.6% | 36.4% | 22.6% |
| FY11 | 88.6% | 39.2% | 25% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$151.6M |
| FY21 | $600K |
| FY20 | $50.5M |
| FY19 | $75.1M |
| FY18 | $107.5M |
| FY17 | $100.1M |
| FY16 | $161.3M |
| FY15 | $116.6M |
| FY14 | $175.9M |
| FY13 | $162.5M |
| FY12 | $132.4M |
| FY11 | $127M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | $0 |
| FY20 | $0 |
| FY19 | $50M |
| FY18 | $0 |
| FY17 | $31.6M |
| FY16 | $162.6M |
| FY15 | $210.7M |
| FY14 | $287.7M |
| FY13 | $146.3M |
| FY12 | $128.5M |
| FY11 | $200.5M |
- Myriad Genetics
- Healthcare median
Show the numbers
| Year | Myriad Genetics | Healthcare median |
|---|---|---|
| FY25 | −44.4% | −30.6% |
| FY24 | −15.2% | −47% |
| FY23 | −34.9% | −58% |
| FY22 | −16.5% | −80.4% |
| FY21 | −3.9% | −71.8% |
| FY20 | −31.2% | −62.2% |
| FY19 | 0.5% | −46.2% |
| FY18 | 17.9% | −49.6% |
| FY17 | 2.4% | −45.9% |
| FY16 | 15.8% | −36% |
| FY15 | 11% | −37.8% |
| FY14 | 22.6% | −35.5% |
| FY13 | 24% | −37.1% |
| FY12 | 22.6% | −29.1% |
| FY11 | 25% | −27.9% |